Stock Detail
Sector:
Latest Quote @ Tue Jun 6 02:50:22 (15 min delayed)
Last Day's Data
| $0.00 |
$0.00 |
$0.00 |
0.00% |
0.00 |
$0.00 |
| $0.00 |
$0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
Stock Profile
Gen-Probe Incorporated engages in the development, manufacture, and marketing of nucleic acid probe-based products for the clinical diagnosis of human diseases, and for the screening of donated human blood. It markets a portfolio of products that use company's technologies to detect various infectious microorganisms, including those causing sexually transmitted diseases, tuberculosis, strep throat, pneumonia, and fungal infections. The company also offers blood-screening assays for the simultaneous detection of human immunodeficiency virus (type 1), hepatitis C virus, and hepatitis B virus presence. In addition, Gen-Probe offers TIGRIS DTS instrument that is used for investigational use in blood screening applications in the United States. The company markets its products to various customers, such as reference laboratories, public health laboratories, and hospitals in North America, Europe, and Japan. It has strategic alliance agreements with Chiron Corporation and Bayer Corporation, as well as has licensing agreements with Corixa Corporation, AdnaGen AG, DiagnoCure, Vysis, Inc., and Organon Teknika B.V. The company also has a collaboration agreement with GE Infrastructure Water and Process Technologies, and Millipore Corp. for developing, manufacturing, and commercializing nucleic acid testing technologies. Gen-Probe Incorporated was founded by David E. Kohne, Thomas H. Adams, and Howard C. Birndorf in 1983. The company is headquartered in San Diego, California.
